Clinton to Propose Crackdown on Inversions
The presidential candidate would impose an "exit tax" on tax inversion deals that let U.S. firms reduce their taxes by merging with companies overseas.
Pfizer Buys Allergan for $160B
The companies predict the combined entity would have more than $25 billion in operating cash flow starting in 2018.
Activist Investor Can’t Dodge Insider Trading Suit
A judge finds Bill Ackman can be sued for allegedly buying a stake in Allergan based on inside information about a takeover bid by Valeant Pharmaceuticals.
Teva to Buy Allergan’s Generic Drug Unit for $40.5B
If the deal is approved, Teva says the combined company would have revenue of about $26 billion and EBITDA of $9.5 billion in 2016.
CEO Pay Lines Up with Shareholder Returns: WSJ Survey
But some CEOs were paid well even though the company delivered lower shareholder returns.
Watchdogs Call for Shorter Window for Activist Disclosures
Groups say loopholes in securities laws allow activist investors to secretly buy large stakes in companies before initiating hostile takeovers.
Salix Calls Off Tax Inversion Deal
The Treasury Department's recent anti-inversion measures claim their first victim — Salix Pharmaceuticals' plan to merge with Italy-based Cosmo.
CFOs on the Move: Week Ending Aug. 22
Spectrum Brands, Allergan, Homejoy, Healthcare Trust, Exco Resources, Alpha and Omega Semiconductor, Health Net, Popeye's Louisiana Kitchen, ITC Holdings
Ackman’s Allergan Takeover Bid Is Easier Said Than Done
The takeover contest's outcome becomes unclear when we consider the conflict between the hedge fund’s objectives and the Allergan board's fiduciary duty.